U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula 2C19H24N2O4.C4H4O4.2H2O
Molecular Weight 840.9124
Optical Activity ( + / - )
Defined Stereocenters 4 / 4
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of FORMOTEROL FUMARATE

SMILES

O.O.OC(=O)\C=C\C(O)=O.COC1=CC=C(C[C@H](C)NC[C@@H](O)C2=CC(NC=O)=C(O)C=C2)C=C1.COC3=CC=C(C[C@H](C)NC[C@@H](O)C4=CC(NC=O)=C(O)C=C4)C=C3

InChI

InChIKey=RATSWNOMCHFQGJ-TUYNVFRMSA-N
InChI=1S/2C19H24N2O4.C4H4O4.2H2O/c2*1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22;5-3(6)1-2-4(7)8;;/h2*3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22);1-2H,(H,5,6)(H,7,8);2*1H2/b;;2-1+;;/t2*13-,19+;;;/m00.../s1

HIDE SMILES / InChI
Molecular Formula C19H24N2O4
Molecular Weight 344.4049
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:43:11 UTC 2023
Edited
by admin
on Fri Dec 15 15:43:11 UTC 2023
Record UNII
W34SHF8J2K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FORMOTEROL FUMARATE
ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
CGP 25827A
Code English
FORMOTEROL FUMARATE [USP MONOGRAPH]
Common Name English
BEVESPI AEROSPHERE COMPONENT FORMOTEROL FUMARATE
Common Name English
FORADIL
Brand Name English
FORMOTEROL FUMARATE DIHYDRATE [EP IMPURITY]
Common Name English
FORMOTEROL FUMARATE DIHYDRATE [VANDF]
Common Name English
PERFORMIST
Brand Name English
FORMOTEROL FUMARATE [VANDF]
Common Name English
FORMOTEROL FUMARATE COMPONENT OF BREZTRI
Brand Name English
(±)-2'-HYDROXY-5'-((R*)-1-HYDROXY-2-(((R*)-P-METHOXY-.ALPHA.-METHYLPHENETHYL)AMINO)ETHYL)FORMANILIDE FUMARATE (2:1) (SALT), DIHYDRATE
Common Name English
Formoterol fumarate dihydrate [WHO-DD]
Common Name English
SYMBICORT COMPONENT FORMOTEROL FUMARATE DIHYDRATE
Brand Name English
FORMOTEROL FUMARATE DIHYDRATE
EP   MI   ORANGE BOOK   VANDF  
Common Name English
FORMOTEROL FUMARATE HYDRATE
JAN  
Common Name English
FORASEQ
Brand Name English
CGP-25827A
Code English
FORMOTEROL FUMARATE [USP-RS]
Common Name English
FORMOTEROL FUMARATE COMPONENT OF DULERA
Common Name English
FORMOTEROL FUMARATE [ORANGE BOOK]
Common Name English
FORMOTEROL FUMARATE COMPONENT OF BEVESPI AEROSPHERE
Common Name English
FORMOTEROL FUMARATE DIHYDRATE [EP MONOGRAPH]
Common Name English
ATOCK
Brand Name English
BD-40A
Code English
YM-08316
Code English
FORMOTEROL FUMARATE [USAN]
Common Name English
DULERA COMPONENT FORMOTEROL FUMARATE
Common Name English
BD 40A
Code English
FORMOTEROL FUMARATE DIHYDRATE [MI]
Common Name English
BREZTRI COMPONENT FORMOTEROL FUMARATE
Brand Name English
FORMOTEROL FUMARATE HYDRATE [JAN]
Common Name English
FORMOTEROL FUMARATE COMPONENT OF DUAKLIR PRESSAIR
Common Name English
FORMOTEROL FUMARATE DIHYDRATE [ORANGE BOOK]
Common Name English
(R*,R*)-(±)-N-(2-HYDROXY-5-(1-HYDROXY-2-((2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENYL)FORMAMIDE, (E)-2-BUTENDIOATE(2:1), DIHYDRATE
Common Name English
OXEZE
Brand Name English
DUAKLIR PRESSAIR COMPONENT FORMOTEROL FUMARATE
Common Name English
TRIMBOW COMPONENT FORMOTEROL FUMARATE DIHYDRATE
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS DUAKLIR GENUAIR (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
EMA ASSESSMENT REPORTS BRETARIS GENUAIR (AUTHORIZED: ASTHMA, PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
NCI_THESAURUS C48149
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
EMA ASSESSMENT REPORTS VYLAER SPIROMAX (AUTHORIZED: ASTHMA, PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
EMA ASSESSMENT REPORTS DUORESP SPIROMAX (AUTHORIZED: ASTHMA, PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
NCI_THESAURUS C319
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
EMA ASSESSMENT REPORTS BUDESONIDA (AUTHORIZED: ASTHMA, PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
EMA ASSESSMENT REPORTS BIRESP SPIROMAX (AUTHORIZED: ASTHMA, PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
Code System Code Type Description
EVMPD
SUB02257MIG
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
MERCK INDEX
m5542
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL1256786
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
EVMPD
SUB25661
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
NCI_THESAURUS
C81648
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
RS_ITEM_NUM
1286107
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
EVMPD
SUB25660
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
RXCUI
236216
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
ALTERNATIVE
PUBCHEM
45358055
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
CAS
183814-30-4
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
FDA UNII
W34SHF8J2K
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
DAILYMED
W34SHF8J2K
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
USAN
JJ-46
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
EPA CompTox
DTXSID5045679
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
SMS_ID
100000090127
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
DRUG BANK
DBSALT001371
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
RXCUI
998038
Created by admin on Fri Dec 15 15:43:11 UTC 2023 , Edited by admin on Fri Dec 15 15:43:11 UTC 2023
PRIMARY
Related Record Type Details
Structure of FORMOTEROL FUMARATE ANHYDROUS
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
Structure of FORMOTEROL FUMARATE ANHYDROUS
ANHYDROUS->SOLVATE
Structure of FORMOTEROL
PARENT -> SALT/SOLVATE
Structure of FORMOTEROL FUMARATE ANHYDROUS
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
Structure of N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]acetamide
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 1-(3-AMINO-4-HYDROXYPHENYL)-2-((2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHANOL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-(2-HYDROXY-5-((1RS)-1-HYDROXY-2-((2-(4-METHOXYPHENYL)ETHYL)AMINO)ETHYL)PHENYL)FORMAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-[2-Hydroxy-5-[1-[[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]amino]-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxy-3-methylphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-(5-((1RS)-2-(BENZYL((1RS)-2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)-1-HYDROXYETHYL)-2-HYDROXYPHENYL)FORMAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
Structure of N-[2-Hydroxy-5-[1-[[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]amino]-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 1-(3-AMINO-4-HYDROXYPHENYL)-2-((2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHANOL
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.75
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-(2-HYDROXY-5-((1RS)-1-HYDROXY-2-(((1SR)-2-(4-METHOXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENYL)FORMAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-Methylformoterol
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]acetamide
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-[2-Hydroxy-5-[1-hydroxy-2-[[2-(4-methoxy-3-methylphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-(2-HYDROXY-5-((1RS)-1-HYDROXY-2-((2-(4-METHOXYPHENYL)ETHYL)AMINO)ETHYL)PHENYL)FORMAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-Methylformoterol
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 4-METHOXYAMPHETAMINE
IMPURITY -> PARENT
The reporting threshold is▲ (IRA 1-Jan-2020) 0.05%
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of FORMOTEROL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966